UCL School of Pharmacy, University College London, 29-39 Brunswick Square, London, WC1N 1AX, UK.
FabRx Ltd, 3 Romney Road, Ashford, Kent, TN24 0RW, UK.
Trends Pharmacol Sci. 2018 May;39(5):440-451. doi: 10.1016/j.tips.2018.02.006. Epub 2018 Mar 11.
3D printing (3DP) is forecast to be a highly revolutionary technology within the pharmaceutical sector. In particular, the main benefits of 3DP lie in the production of small batches of medicines, each with tailored dosages, shapes, sizes and release characteristics. The manufacture of medicines in this way may finally lead to the concept of personalised medicines becoming a reality. In the shorter term, 3DP could be extended throughout the drug development process, ranging from preclinical development and clinical trials, through to frontline medical care. In this review, we provide a timely perspective on the motivations and potential applications of 3DP pharmaceuticals, as well as a practical viewpoint on how 3DP could be integrated across the pharmaceutical space.
3D 打印（3DP）预计将成为制药领域一项极具革命性的技术。特别是，3DP 的主要优势在于能够生产小批量的药物，每批药物都具有定制的剂量、形状、大小和释放特性。以这种方式制造药物最终可能会使个性化药物的概念成为现实。从短期来看，3DP 可以扩展到药物开发过程的各个环节，从临床前开发和临床试验到一线医疗。在这篇综述中，我们及时地探讨了 3DP 制药的动机和潜在应用，以及 3DP 如何在制药领域中得到整合的实用观点。
